Move Together Boston Feasibility Pilot (Sit Less, Move More App for Black Breast Cancer Survivors & At-Risk Relatives)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05011279 |
Recruitment Status :
Completed
First Posted : August 18, 2021
Results First Posted : May 8, 2023
Last Update Posted : November 15, 2023
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Study Type | Interventional |
---|---|
Study Design | Allocation: N/A; Intervention Model: Single Group Assignment; Masking: None (Open Label); Primary Purpose: Supportive Care |
Conditions |
Breast Cancer Survivor Breast Cancer Fitness Trackers |
Intervention |
Other: Move Together app/Garmin Activity Tracker |
Enrollment | 10 |
Recruitment Details | |
Pre-assignment Details |
Arm/Group Title | Pilot Study |
---|---|
Arm/Group Description |
Participants in the pilot study will participate as members of family-based dyads (n=5 dyads) in this single arm study. One member of each dyad will be a breast cancer survivor and one will be a blood relative. Study involves interviews, questionnaires, Use of Move Together app with Garmin activity tracker watch Move Together app/Garmin Activity Tracker: - The Move Together app allows users to set daily goals for increasing physical activity and decreasing sedentary time, track progress on goals, message their buddy, and access external educational infographics and other resource links. -Garmin activity tracker in this study is for participants to track their steps and sedentary time. |
Period Title: Overall Study | |
Started | 10 [1] |
Completed | 10 [1] |
Not Completed | 0 |
[1]
5 survivors and 5 relatives
|
Arm/Group Title | Pilot Study | |
---|---|---|
Arm/Group Description |
Participants in the pilot study will participate as members of family-based dyads (n=5 dyads). One member of each dyad will be a breast cancer survivor and one will be a blood relative. Study involves interviews, questionnaires, Use of Move Together app with Garmin activity tracker watch Move Together app/Garmin Activity Tracker: - The Move Together app allows users to set daily goals for increasing physical activity and decreasing sedentary time, track progress on goals, message their buddy, and access external educational infographics and other resource links. -Garmin activity tracker in this study is for participants to track their steps and sedentary time. |
|
Overall Number of Baseline Participants | 10 | |
Baseline Analysis Population Description |
this includes 5 survivors and 5 relatives
|
|
Age, Categorical
Measure Type: Count of Participants Unit of measure: Participants |
||
Number Analyzed | 10 participants | |
<=18 years |
0 0.0%
|
|
Between 18 and 65 years |
8 80.0%
|
|
>=65 years |
2 20.0%
|
|
Age, Continuous
Mean (Full Range) Unit of measure: Years |
||
Number Analyzed | 10 participants | |
45.9
(22 to 70)
|
||
Sex: Female, Male
Measure Type: Count of Participants Unit of measure: Participants |
||
Number Analyzed | 10 participants | |
Female |
10 100.0%
|
|
Male |
0 0.0%
|
|
Race (NIH/OMB)
Measure Type: Count of Participants Unit of measure: Participants |
||
Number Analyzed | 10 participants | |
American Indian or Alaska Native |
0 0.0%
|
|
Asian |
0 0.0%
|
|
Native Hawaiian or Other Pacific Islander |
0 0.0%
|
|
Black or African American |
10 100.0%
|
|
White |
0 0.0%
|
|
More than one race |
0 0.0%
|
|
Unknown or Not Reported |
0 0.0%
|
|
Region of Enrollment
Measure Type: Number Unit of measure: Participants |
||
United States | Number Analyzed | 10 participants |
10 | ||
Breast Cancer Status
Measure Type: Count of Participants Unit of measure: Participants |
||
Number Analyzed | 10 participants | |
Survivor |
5 50.0%
|
|
Mother of a survivor, no BRCA |
1 10.0%
|
|
Daughter of a survivor, no BRCA |
1 10.0%
|
|
Sister of a survivor, no BRCA |
2 20.0%
|
|
Niece of a survivor, no BRCA |
1 10.0%
|
Name/Title: | Catherine Marinac |
Organization: | Dana-Farber Cancer Institute |
Phone: | 617-632-4703 |
EMail: | CatherineR_Marinac@dfci.harvard.edu |
Responsible Party: | Catherine Marinac, PhD, Dana-Farber Cancer Institute |
ClinicalTrials.gov Identifier: | NCT05011279 |
Other Study ID Numbers: |
20-104 U54CA156732 ( U.S. NIH Grant/Contract ) |
First Submitted: | August 13, 2021 |
First Posted: | August 18, 2021 |
Results First Submitted: | December 28, 2022 |
Results First Posted: | May 8, 2023 |
Last Update Posted: | November 15, 2023 |